Pharmaceutical composition and application thereof in preparation of anti-osteoporosis drugs

Abstract

The invention discloses a pharmaceutical composition and application thereof in preparation of anti-osteoporosis drugs. The pharmaceutical composition is prepared from the following components in parts by mass: 7.64 to 40.90 parts of mangiferin, 4.26 to 7.39 parts of tetrahydroepiberberine, 24.33 to 35.31 parts of phellodendrine, 10.11 to 14.64 parts of magnoflorine, 2.30 to 4.26 parts of 13-hydroxyl oxidized berberine, 0.12 to 0.29 part of palmatine and 17.96 to 30.71 parts of berberine. The pharmaceutical composition not only can significantly reduce blood sugar, but also can significantly improve the skull area and skull optical density of the zebra fish with diabetic osteoporosis; the activity of alkaline phosphatase is improved, and bone formation related gene expression is promoted; the activity of tartrate-resistant acid phosphatase is reduced, and the expression of bone resorption related genes is reduced; the traditional Chinese medicine composition is safe and reliable to use, and has a good research and development prospect of anti-osteoporosis medicines.

Description

technical field [0001] The invention belongs to the technical field of diabetes treatment, and in particular relates to a pharmaceutical composition and its application in the preparation of anti-osteoporosis drugs. Background technique [0002] Diabetic osteoporosis is a systemic and metabolic skeletal disease that is prone to fractures in diabetes complicated by osteopenia, changes in bone microstructure, and increased bone fragility. The incidence rate in diabetic patients is as high as 60%, and it has become a long-term severe pain. and main causes of dysfunction. [0003] In the current clinical treatment of diabetic osteoporosis, bone resorption inhibitors (such as bisphosphonates, hormones, calcitonin, etc.) and bone formation promoters (such as parathyroid hormone analogue peptide, etc.) are generally used; however, the above treatment There are still many deficiencies in the drug, which are mainly manifested in: (1) after long-term use of bone resorption inhibitors...

AI Technical Summary

Problems solved by technology

[0003] In the current clinical treatment of diabetic osteoporosis, bone resorption inhibitors (such as bisphosphonates, hormones, calcitonin, etc.) and bone formation promoters (such as parathyroid hormone analogue peptide, etc.) are generally used; however, the above treatment There are still many deficiencies in the drug, which are mainly manifested in: (1) after long-term use of bone resorption inhibitors, side effects such as mandibular necrosis, atypical femoral fractures, high incidence of heart disease and breast cancer are prone to occur; (2) bone formation accelerators have Risk of osteosarcoma or other bone tumors

[0004] Since the pathogenesis of diabetic osteoporosis is relatively complex, only relying on osteoporosis drugs or diabetes drugs for treatment cannot block the key pathological links of diabetic osteoporosis, resulting in unsatisfactory treatment effects

Images